多施設による緑内障患者の実態調査2016年版—配合点眼薬の使用

Current status of therapy for glaucoma at multiple ophthalmic institutions in 2016 — Fixed combination eye drops

要約　目的：緑内障患者の治療実態を調査し，配合点眼薬の使用状況を検討した。

対象と方法：57施設に受診した緑内障，高眼圧症4,288例の使用薬剤を調査し，さらに2012年の前回調査と比較した。

結果：PG/β配合点眼薬とCAI/β配合点眼薬の使用は，2剤例28.7％と10.0％，3剤例21.7％と44.0％，4剤以上例17.9％と63.2％であった。2剤はPG/β配合点眼薬，3剤以上はCAI/β配合点眼薬が多かった。前回調査と比較し，PG/β配合点眼薬は2，3剤例で，CAI/β配合点眼薬は多剤併用では有意に増加した。

結論：配合点眼薬は多剤併用例では60％以上で使用され，経年変化でも増加している。

Abstract　Purpose：We investigated fixed combination drug therapy in glaucoma patients.

Subjects and Methods：A total of 4,288 eyes of 4,288 patients with glaucoma and ocular hypertension from 57 ophthalmic institutions were included. The results were compared with those of a previous study performed in 2012.

Results：Participants were divided into several groups, based on the number of medications. A total of 28.7％ and 10.0％ patients used prostaglandin（PG）/β-blockers fixed combination（PG/βFC）and carbonic anhydrase inhibitors（CAI）/β-blockers fixed combination（CAI/βFC）in 2 medications group, 21.7％ and 44.0％ patients used PG/βFC and CAI/βFC in 3 medications group, and 17.9％ and 63.2％ patients used PG/βFC and CAI/βFC in≧4 medications group, respectively. PG/βFC was the most frequently used drug in 2 medications group, CAI/βFC was the most frequently used drug in≧3 medications group. The patients using PG/βFC were increased in 2 or 3 medications groups, whereas the patients using CAI/βFC were increased in all medication groups compared to previous study.

Conclusion：More than 60％ patients used fixed combination drug in all medication groups, the patients using fixed combination were increased.